




CV Template of KATRD International Conference 2021

Name	Hirofumi Chiba			
First Name	Hirofumi	Last Name	Chiba	
Country	Japan			
Organization	Department of Respiratory and Allergic Medicine, Sapporo Medical University			
Current Position	Associate Professor			

Educational Background

March 1999: Ph.D., Sapporo Medical University, Hokkaido, Japan

March 1993: M.D., Sapporo Medical University, Hokkaido, Japan

Professional Experiences

2015–Present: Associate Professor, Department of Respiratory and Allergic Medicine, Sapporo Medical University, Hokkaido, Japan.

2011–2015: Lecturer, Department of Respiratory and Allergic Medicine, Sapporo Medical University, Hokkaido, Japan.

2002–2011: Assistant Professor, Department of Internal Medicine, Sapporo Medical University, Hokkaido, Japan.

2000–2002: Study abroad, National Jewish Medical and Research Center, Denver, CO, USA.

1999–2000: Assistant Professor, Department of Biochemistry, Sapporo Medical University, Hokkaido, Japan.

1993–1999: Residency, Department of Respiratory and Allergic Medicine, Sapporo Medical University, Hokkaido, Japan.

Professional Organizations

- [1] Japanese Society of Internal Medicine (training doctor, certified physician, general internal medicine specialist, general internal medicine specialist qualification examination committee)
- [2] Japanese Respiratory Society (training doctor, specialist, director, gender equality committee vice chairman, terminology committee vice chairman)
- [3] Japanese Society of Respiratory Endoscopy (bronchoscope specialist)
- [4] Japanese Lung Cancer Society
- [5] Japanese Society of Allergology
- [6] Japanese Society for Tuberculosis
- [7] Japanese Medical Society for Lung Surfactant and Biological Interface



Main Scientific Publications

- [1] Chiba H. et al, Human surfactant protein D (SP-D) binds *Mycoplasma pneumoniae* by high affinity interactions with lipids. *J Biol Chem.* 2002; 277: 20379-20385.
- [2] Piboonpocanun S, Chiba H. et al. Surfactant protein A binds *Mycoplasma pneumoniae* with high affinity and attenuates its growth by recognition of disaturated phosphatidylglycerols. *J Biol Chem.* 2005; 280: 9-17.
- [3] Nishikiori H, Chiba H. et al. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. *BMC pulm Med* 2014; 8; 1: 196.
- [4] Natsuzaka M, Chiba H. et al. Epidemiologic survey of Japanese Patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. *Am J Respir Crit Care Med* 2014; 190: 773-779.
- [5] Kondoh S, Chiba H. et al. Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis. *Respir Investig.* 2016;54:327-333.
- [6] Kondoh Y, Chiba H. et al. Disease severity staging system for idiopathic pulmonary fibrosis in Japan. *Respirology.* 2017;22:1609-1614.
- [7] Ikeda K, Chiba H. et al. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. *Respir Med.* 2017;131:184-191.
- [8] Takahashi Y, Chiba H. et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. *Respir Res.* 2018;19:34.
- [9] Taya T, Chiba H. et al. Risk factors for acute exacerbation of idiopathic interstitial pneumonia in patients undergoing lung cancer treatment. *Jpn J Clin Oncol.* 2019 ; 49 : 1126-1133.
- [10] Asai Y, Chiba H. et al. Aberrant populations of circulating T follicular helper cells and regulatory B cells underlying idiopathic pulmonary fibrosis. *Respir Res.* 2019 ; 20(1) : 244.
- [11] Mori Y, Chiba H. et al. Respiratory reactance in forced oscillation technique reflects disease stage and predicts lung physiology deterioration in idiopathic pulmonary fibrosis. *Respir Physiol Neurobiol.* 2020 ; 275 : 103386.
- [12] Yoshikawa T, Chiba H. et al. Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. *BMC Pulm Med.* 2020;20:27.
- [13] Nishikiori H, Chiba H, Park MS. et al. Modifying the GAP Model for East Asian Populations with Idiopathic Pulmonary Fibrosis. *Respir Investig.* 2020;58(5):395-402.
- [14] Kameda M, Chiba H. et al. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features. *PLoS One.* 2020;15(11): e0241719.
- [15] Ikeda K, Chiba H. et al. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. *Respir Res.* 2020; 21(1):316.